Source comparison
CJC-1295 Pharmacokinetics: Peptide Comparison
CJC-1295 (with DAC) 6–8 days Albumin-bound GHRH analog; DAC prevents renal clearance and enzymatic degradation Once weekly Optimal for research requiring sustained GH elevation without daily dosing burden. DAC modification is the gold standard for extended-rel
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- 6–8 days
- Albumin-bound GHRH analog; DAC prevents renal clearance and enzymatic degradation
- Once weekly
- Optimal for research requiring sustained GH elevation without daily dosing burden. DAC modification is the gold standard for extended-release GHRH pharmacokinetics.
- Sermorelin (GHRH 1-29)
- ~10 minutes
- Unmodified GHRH analog; rapid DPP-4 cleavage at N-terminus
- 2–3 times daily
- Shortest half-life of any GHRH analog. Useful for mimicking physiological pulsatility but impractical for research protocols requiring stable baseline GH levels.
- Modified GRF (1-29) / CJC-1295 without DAC
- ~30 minutes
- GHRH analog with DPP-4 resistance but no albumin binding
- Modest half-life extension vs sermorelin, but still requires multiple daily doses. Lacks the pharmacokinetic advantages that make CJC-1295 (with DAC) viable for weekly dosing.
- Tesamorelin
- ~26 minutes
- Stabilized GHRH analog; resistant to DPP-4 but subject to other proteases
- Once daily (clinical use)
- FDA-approved for HIV-associated lipodystrophy. Half-life allows once-daily dosing in clinical settings but doesn't approach the multi-day duration of CJC-1295 pharmacokinetics.